GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Harvard Bioscience Inc (NAS:HBIO) » Definitions » Cyclically Adjusted FCF per Share

Harvard Bioscience (Harvard Bioscience) Cyclically Adjusted FCF per Share : $0.09 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Harvard Bioscience Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Harvard Bioscience's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.016. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.09 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Harvard Bioscience's average Cyclically Adjusted FCF Growth Rate was 12.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -6.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -13.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -12.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Harvard Bioscience was 7.10% per year. The lowest was -18.60% per year. And the median was -8.70% per year.

As of today (2024-05-26), Harvard Bioscience's current stock price is $3.16. Harvard Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.09. Harvard Bioscience's Cyclically Adjusted Price-to-FCF of today is 35.11.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Harvard Bioscience was 81.80. The lowest was 10.22. And the median was 21.28.


Harvard Bioscience Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Harvard Bioscience's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Bioscience Cyclically Adjusted FCF per Share Chart

Harvard Bioscience Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.11 0.10 0.07 0.09

Harvard Bioscience Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.09 0.09 0.09

Competitive Comparison of Harvard Bioscience's Cyclically Adjusted FCF per Share

For the Medical Instruments & Supplies subindustry, Harvard Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Bioscience's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Harvard Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Harvard Bioscience's Cyclically Adjusted Price-to-FCF falls into.



Harvard Bioscience Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Harvard Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.016/131.7762*131.7762
=0.016

Current CPI (Mar. 2024) = 131.7762.

Harvard Bioscience Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.029 100.560 0.038
201409 0.004 100.428 0.005
201412 0.014 99.070 0.019
201503 -0.047 99.621 -0.062
201506 -0.031 100.684 -0.041
201509 -0.022 100.392 -0.029
201512 0.032 99.792 0.042
201603 -0.027 100.470 -0.035
201606 0.022 101.688 0.029
201609 0.084 101.861 0.109
201612 0.035 101.863 0.045
201703 -0.024 102.862 -0.031
201706 0.007 103.349 0.009
201709 0.054 104.136 0.068
201712 -0.033 104.011 -0.042
201803 -0.002 105.290 -0.003
201806 0.031 106.317 0.038
201809 -0.046 106.507 -0.057
201812 0.068 105.998 0.085
201903 0.050 107.251 0.061
201906 0.010 108.070 0.012
201909 0.074 108.329 0.090
201912 0.047 108.420 0.057
202003 0.069 108.902 0.083
202006 0.054 108.767 0.065
202009 0.027 109.815 0.032
202012 0.056 109.897 0.067
202103 0.018 111.754 0.021
202106 0.014 114.631 0.016
202109 -0.028 115.734 -0.032
202112 -0.006 117.630 -0.007
202203 -0.060 121.301 -0.065
202206 -0.015 125.017 -0.016
202209 0.005 125.227 0.005
202212 0.059 125.222 0.062
202303 0.037 127.348 0.038
202306 0.069 128.729 0.071
202309 0.093 129.860 0.094
202312 0.076 129.419 0.077
202403 0.016 131.776 0.016

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Harvard Bioscience  (NAS:HBIO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Harvard Bioscience's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=3.16/0.09
=35.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Harvard Bioscience was 81.80. The lowest was 10.22. And the median was 21.28.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Harvard Bioscience Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Harvard Bioscience's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Bioscience (Harvard Bioscience) Business Description

Traded in Other Exchanges
Address
84 October Hill Road, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life science and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Executives
James W Green director, officer: Chief Executive Officer 12525 CHADRON AVENUE, HAWTHORNE CA 90250
Alan I Edrick director 20200 SUNBURST STREET, CHATSWORTH CA 91311
Jennifer Cote officer: Interim CFO C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Bertrand Loy director C/O ENTEGRIS, INC., 129 CONCORD RD, BILLERICA MA 01821
Thomas W Loewald director 81 WYMAN STREET, WALTHAM MA 02451
John F Kennedy director C/O NET PERCEPTIONS INC, 7700 FRANCE AVE. SOUTH, EDINA MN 55435
Katherine A. Eade director C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Susan M. Steele director C/O HILL INTERNATIONAL, INC., 2005 MARKET ST., 17TH FLOOR, PHILADELPHIA PA 19103
Kenneth Fletcher Olson officer: Chief Operating Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Michael A. Rossi officer: Chief Financial Officer C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Yash Singh officer: Executive Vice President C/O HARVARD BIOSCIENCE, INC., 84 OCTOBER HILL ROAD #10, HOLLISTON MA 01746
Jeffrey Duchemin officer: Chief Executive Officer 14 EASTLAND TERRACE, HAVERHILL MA 01830
Kamalam Unninayar officer: Chief Financial Officer C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Robert E. Gagnon officer: Chief Financial Officer C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
George Uveges director C/O MFIC CORPORATION, 30 OSSIPEE ROAD, NEWTON MA 02464